NEUP
Neuphoria Therapeutics Inc.
$3.38
-0.17 (-4.79%)
At close · Jul 2
Market Cap
$18.27M
Shares
5,404,551
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.38
Open$3.36
Day$3.30–3.50
52W$3.19–21.40
Avg vol 30d90K
Short int23K · 0.4% float · 1.0d
Short vol10%
Last earningsMay 20, 2025
DataDec 2021–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Strong Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−41% below
−
Price vs 50-day avg
−30% below
◦
RSI (14)
26 · oversold
−
MACD trend
negative
−
52-week position
1% · near low
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $5 › 200d $6 — 200d above 50d
−
Institutional flow
-10% holders QoQ · +6 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
0.43% of float · ▼ -37.5% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
19 holders — mid 1-yr range
Fundamentals
Excellent
+
EPS growth
+99% Y/Y
+
Balance sheet
net cash $14.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−41% below
Bearish
Price vs 50-day avg
−30% below
Bearish
RSI (14)
26 · oversold
Neutral
MACD trend
negative
Bearish
52-week position
1% · near low
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.43% of float · ▼ -37.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $3
Now $3 · 1%
52-wk high $21
vs 200-day avg -41%
vs 50-day avg -30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEUP
this stock
Neuphoria Therapeutics Inc.
|
$18.27M | -12.9% | — | — | 0.4% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEUP | -22.3% | -28.1% | -17.0% | -22.7% | -12.9% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -23.7% | -26.8% | -25.0% | -22.4% | -22.1% |